Mainz Biomed B.V. (MYNZ) Research

Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.

Market snapshot

Symbol
MYNZ
Price
$3.59
Day change
+0.84%
Market cap
$22.0M
P/E ratio
-2.47x
52-week range
0.5476-5.34
Sector
Healthcare
Industry
Medical - Diagnostics & Research

Peer companies

  • BNB Plus Corp. (BNBX)
  • Bionano Genomics, Inc. (BNGO)
  • Check-Cap Ltd. (CHEK)
  • Flora Growth Corp. (FLGC)
  • GBS Inc. (GBS)
  • HeartSciences Inc. (HSCS)
  • Impact BioMedical Inc. (IBO)
  • Pasithea Therapeutics Corp. (KTTA)

Recent insider activity

  • Ben-Tzvi Avraham — A-Award (137141 shares) on 2026-05-08
  • NATAN DAVID — A-Award (137141 shares) on 2026-05-08
  • Lazar David E. — A-Award (1000000 shares) on 2026-04-22
  • Lazar David E. — A-Award (1000000 shares) on 2026-04-22
  • Lazar David E. — A-Award (1000000 shares) on 2026-02-13

Open Mainz Biomed B.V. (MYNZ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.